Dernière mise à jour : 02 septembre 2016
Détails
FichiersGeneric Name:
Pazopanib Hydrochloride
État du projet:
Terminé
Domaine thérapeutique:
Soft Tissue Sarcoma
Fabricant:
GlaxoSmithKline Inc.
Brand Name:
Votrient
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0009-000
Indicateur de rendement:
S. O. – Mesures de rendement prédictives
Strength:
200 mg
Tumour Type:
Sarcoma
Indications:
Soft Tissue Sarcoma (STS)
Funding Request:
Adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy. Funding is not requested for patients with GIST and adipocytic soft tissue sarcomas.
Review Status:
Complete
Pre Noc Submission:
Yes
Date NOC Issued:
Sponsor:
GlaxoSmithKline Inc.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Ne pas rembourser
pERC Meeting:
Final Recommendation Issued:
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 02 septembre 2016